Welcome to our dedicated page for Solventum Corporation SEC filings (Ticker: SOLV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Solventum Corporation (NYSE: SOLV) SEC filings page on Stock Titan provides access to the company’s official regulatory disclosures filed with the U.S. Securities and Exchange Commission. These documents help investors, analysts and other stakeholders understand Solventum’s financial performance, portfolio actions, capital structure and governance as it operates in the medical instruments and supplies sector.
Solventum uses current reports on Form 8-K to disclose a variety of material events. Examples include 8-K filings reporting quarterly financial results, such as third-quarter 2025 earnings, which incorporate press releases detailing segment performance, non-GAAP measures and updated guidance. Other 8-K filings describe material definitive agreements and their completion, such as the transaction agreement and subsequent closing of the sale of certain assets and liabilities related to Solventum’s purification and filtration business to Thermo Fisher Scientific Inc.
Additional 8-K filings cover capital markets and balance sheet activities, including the commencement, upsizing and pricing of cash tender offers for specified series of senior notes, and an underwriting agreement relating to the sale of shares by a selling shareholder. Governance and leadership changes, such as the appointment of a Chief Commercial Officer and the departure of a segment leader, are also reported on Form 8-K, along with information about related compensation and severance arrangements.
On Stock Titan, users can review these filings alongside AI-powered summaries that explain key points in clear language. This includes highlighting where Solventum discusses its “Transform for the Future” initiative, outlines risk factors, or provides pro forma financial information related to divestitures. The filings page is also a resource for tracking Solventum’s capital allocation strategy, including debt reduction, note tender offers and the authorization of a share repurchase program, as disclosed in its official documents.
Solventum reported weaker Q1 2026 results, with profit sharply lower despite modest segment growth. Net sales slipped 3% to $2,007 million, while net income fell to $13 million from $137 million, and diluted EPS dropped to $0.07 from $0.78.
MedSurg sales rose 6.6% to $1,234 million, Dental Solutions grew 7.9% to $354 million, and Health Information Systems increased 4.1% to $342 million, but MedSurg margins compressed as tariffs, inflation and separation-related costs outpaced savings. Company‑wide operating margin declined to 4.0% from 7.3%.
Cash flow from operations turned negative at $(189) million versus $29 million a year earlier, reflecting higher incentive and transition payments. Cash and equivalents decreased to $561 million, while total debt stood at $5,080 million. Solventum booked $37 million of new "Transform for the Future" restructuring charges and repurchased 922,636 shares for $67 million under a $1 billion buyback authorization.
Solventum reported mixed first-quarter 2026 results, with lower reported sales but stronger underlying trends and reaffirmed guidance. Net sales were $2.007 billion, down 3.0% year over year, while organic sales grew 2.1% across all reportable segments. GAAP diluted EPS fell to $0.07 from $0.78, largely reflecting separation, restructuring and other one-time items, but adjusted diluted EPS rose 10.6% to $1.48. GAAP operating margin declined to 4.0%, while adjusted operating margin was 19.5%, slightly below 19.7% a year earlier. Operating cash flow was $(189) million and free cash flow was $(273) million, pressured by separation activities, transition payments and seasonality. The company affirmed full-year 2026 organic sales growth of 2.0%–3.0%, expects adjusted EPS toward the high end of its $6.40–$6.60 range, and targets about $200 million of free cash flow. Solventum also highlighted a new 250,000 square foot R&D center and a major manufacturing expansion to support future growth.
Solventum Corp director Wendell Amy McBride exercised restricted stock units into common shares. On April 30, 2026, 3,403 Restricted Stock Units (RSUs), each representing a contingent right to receive 1 share of common stock, were settled into 3,403 shares of common stock at a stated price of $0.00 per share.
Following this exercise, McBride directly holds 10,422 shares of Solventum common stock, and the RSU balance related to this grant is now shown as 0 units. The footnotes state that the RSUs involved were fully vested before settlement.
Solventum Corp director John H. Weiland exercised 3,403 Restricted Stock Units into 3,403 shares of Common Stock on April 30, 2026. The RSUs were fully vested and carried a conversion price of $0.00 per unit, giving him common shares without a cash outlay.
After this settlement, Weiland directly holds 8,947 shares of Common Stock and no remaining RSUs from this grant. This filing reflects a compensation-related derivative exercise rather than an open-market purchase or sale.
Solventum Corp director Mily Elizabeth exercised restricted stock units into common shares. On April 30, 2026, 3,403 Restricted Stock Units were converted into 3,403 shares of Solventum common stock at a stated price of $0.00 per share, reflecting a compensation-related equity settlement rather than a market purchase.
Following this exercise, Elizabeth directly held 9,009 shares of Solventum common stock. The RSUs referenced were fully vested and each RSU represented a contingent right to receive one share of common stock upon settlement. The filing shows no open-market sales or tax-withholding dispositions linked to this transaction.
Solventum Corp director Wilson Darryl L. exercised fully vested restricted stock units to receive 3,403 shares of Common Stock on April 30, 2026. The RSUs represented a contingent right to receive one share of common stock per unit upon settlement.
After this non-cash derivative exercise, he directly holds 8,947 shares of Solventum common stock. No open-market purchases or sales were reported in this filing.
Solventum Corp director Karen J. May exercised 3,403 Restricted Stock Units into Common Stock. Each RSU converted into 1 share of Solventum Common Stock at a stated price of $0.00 per unit.
Following the transaction, she directly holds 8,947 shares of Common Stock, and the exercised RSUs are now fully settled. The filing shows an option-style conversion but no open-market sale or purchase of shares.
Solventum Corp director Harris Bernard A Jr exercised previously granted Restricted Stock Units (RSUs) into common stock. He acquired 3,403 shares of Solventum common stock through the conversion of fully vested RSUs, and now directly holds 8,947 common shares in total. No shares were sold in this filing.
Solventum Corp director Glenn A. Eisenberg reported a routine equity compensation event. On April 30, 2026, he exercised fully vested Restricted Stock Units (RSUs) covering 3,403 shares of Common Stock, converting them into directly held shares.
Following this settlement, Eisenberg directly holds 8,947 shares of Solventum Common Stock. The RSUs represented a contingent right to receive one share of Common Stock per unit upon settlement, and all such RSUs referenced in this filing are now fully settled, with no remaining RSU balance shown.
Solventum Corp director Shirley Ann Edwards exercised 3,403 restricted stock units into 3,403 shares of Common Stock. The RSUs were fully vested and converted at a stated price of $0.00 per share. Following the transaction, she directly holds 8,947 shares of Solventum Common Stock. No open-market purchases or sales were reported; this reflects a compensation-related derivative exercise.